CIDP-MGUS (non-IgM) has the same clinical and electrodiagnostic characteristics as pure CIDP and has the same treatment choice and algorithms (please note however that many neurologists still try standard CIDP treatments first before considering immunosuppression, even though they are not as effective as in idiopathic CIDP) [12]. This evidence concerns the gene CD40LG and chronic inflammatory demyelinating polyradiculoneuropathy.